Memantine (Namenda) for moderate to severe Alzheimer's disease

被引：0
|
作者：
Ables, AZ [1 ]
机构：
[1] Spartanburg Family Med Residency Program, Spartanburg, SC USA
来源：
AMERICAN FAMILY PHYSICIAN | 2004年 / 69卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Synopsis: Memantine (Namenda) is an N-methyl-d-aspartate'(NMDA) receptor blocker indicated for the treatment of moderate to severe Alzheimer's disease (AD). The NMDA receptor is activated by glutamate, the primary excitatory neurotransmitter in the brain. Overstimulation by glutamate may result in neuronal damage and has been implicated in neurodegenerative disorders such as AD. Memantine is the first pharmacologic agent approved by the US. Food and Drug Administration for the treatment of moderate to severe AD.
引用
收藏
页码：1491 / 1492
页数：2
相关论文
共 50 条
  • [21] Memantine positively influences behaviour in moderate to severe Alzheimer's disease
    Möbius, HJ
    Stöffler, A
    Wirth, Y
    Gauthier, S
    NEUROBIOLOGY OF AGING, 2004, 25 : S19 - S19
  • [22] Memantine A Review of its Use in Moderate to Severe Alzheimer's Disease
    McKeage, Kate
    CNS DRUGS, 2009, 23 (10) : 881 - 897
  • [23] Memantine benefits functional abilities in moderate to severe Alzheimer’s disease
    Bengt Winblad
    S. Gauthier
    D. Åström
    K. Stender
    The journal of nutrition, health & aging, 2010, 14 : 770 - 774
  • [24] Memantine benefits on functional abilities in moderate to severe Alzheimer's disease
    Winblad, B.
    Hefting, N.
    Loft, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 185 - 186
  • [25] Spotlight on Memantine in Moderate to Severe Alzheimer’s Diseasey
    Kate McKeage
    Drugs & Aging, 2010, 27 : 177 - 179
  • [26] Memantine has positive effects on behaviour in moderate to severe Alzheimer's disease
    Gauthier, S.
    Wirth, Y.
    Stoeffler, A.
    Moebius, H. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 188 - 188
  • [27] Added Therapeutic Value of Memantine in the Treatment of Moderate to Severe Alzheimer’s Disease
    T. Heinen-Kammerer
    H. Rulhoff
    S. Nelles
    R. Rychlik
    Clinical Drug Investigation, 2006, 26 : 303 - 314
  • [28] Added therapeutic value of memantine in the treatment of moderate to severe Alzheimer's disease
    Heinen-Kammerer, T.
    Rulhoff, H.
    Nelles, S.
    Rychlik, R.
    CLINICAL DRUG INVESTIGATION, 2006, 26 (06) : 303 - 314
  • [29] Memantine and individual activities of daily living in moderate to severe Alzheimer's disease
    Feldman, H
    Schmitt, FA
    Doraiswamy, PM
    Graham, SM
    Bell, JM
    NEUROLOGY, 2005, 64 (06) : A103 - A104
  • [30] Memantine Improves Functional Communication in Patients with Moderate to Severe Alzheimer's Disease
    Tariot, Pierre N.
    Saxton, Judith
    Tocco, Michael
    Hofbauer, Robert K.
    Resnick, Malca
    Graham, Stephen M.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 16 (03): : A110 - A110
12345